
Journey Medical Corporation (NASDAQ:DERM – Free Report) – HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for Journey Medical in a research note issued on Friday, November 13th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings of ($0.26) per share for the year, up from their prior estimate of ($0.29). HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Journey Medical’s current full-year earnings is ($0.13) per share. HC Wainwright also issued estimates for Journey Medical’s FY2028 earnings at $0.31 EPS, FY2029 earnings at $0.47 EPS and FY2030 earnings at $0.51 EPS.
Journey Medical (NASDAQ:DERM – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.03). The firm had revenue of $18.97 million for the quarter, compared to analysts’ expectations of $20.32 million. Journey Medical had a negative return on equity of 16.15% and a negative net margin of 7.34%.
A number of other equities research analysts have also weighed in on the stock. B. Riley Financial restated a “buy” rating and issued a $13.00 price objective (down from $15.00) on shares of Journey Medical in a report on Friday. Zacks Research downgraded shares of Journey Medical from a “hold” rating to a “strong sell” rating in a research note on Thursday, November 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Journey Medical in a research note on Thursday, October 15th. Finally, Wall Street Zen lowered Journey Medical from a “buy” rating to a “hold” rating in a report on Saturday, October 17th. Two analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $13.00.
View Our Latest Stock Report on Journey Medical
Journey Medical Stock Performance
Shares of Journey Medical stock opened at $3.70 on Tuesday. The company has a current ratio of 1.59, a quick ratio of 1.41 and a debt-to-equity ratio of 0.64. Journey Medical has a 52-week low of $3.64 and a 52-week high of $9.56. The company has a 50 day moving average of $5.81 and a 200 day moving average of $6.45.
Hedge Funds Weigh In On Journey Medical
Hedge funds have recently added to or reduced their stakes in the stock. Jump Financial LLC acquired a new stake in Journey Medical during the third quarter worth approximately $81,000. Marshall Wace LLP boosted its holdings in shares of Journey Medical by 38.9% in the 3rd quarter. Marshall Wace LLP now owns 194,311 shares of the company’s stock valued at $1,329,000 after buying an additional 54,468 shares in the last quarter. First Eagle Investment Management LLC acquired a new position in shares of Journey Medical in the 3rd quarter valued at $3,305,000. Allegiance Financial Group Advisory Services LLC acquired a new position in shares of Journey Medical in the 3rd quarter valued at $68,000. Finally, Salem Investment Counselors Inc. grew its position in shares of Journey Medical by 21.0% in the 3rd quarter. Salem Investment Counselors Inc. now owns 35,319 shares of the company’s stock valued at $242,000 after buying an additional 6,119 shares during the last quarter. 7.25% of the stock is currently owned by hedge funds and other institutional investors.
Journey Medical Company Profile
Journey Medical Corporation is a commercial-stage pharmaceutical company focused on developing and marketing prescription treatments for dermatological conditions. Founded in 2014 and based in Scottsdale, Arizona, the company primarily serves the U.S. market. Its portfolio includes treatments for conditions such as acne, rosacea, excessive underarm sweating and fungal skin infections. Products include Amzeeq and Zilxi, topical minocycline therapies; Qbrexza, a topical treatment for primary axillary hyperhidrosis; and the oral rosacea treatment Emrosi.
Featured Articles
- Five stocks we like better than Journey Medical
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Journey Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Journey Medical and related companies with MarketBeat.com's FREE daily email newsletter.
